## **Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

1-38. (canceled)

- 39. (withdrawn) A polypeptide having an amino acid sequence as set out in SEQ ID NO:1 from amino acid 37 to 1114, or a sequence having at least 50% identity thereto, or a functional fragment thereof.
- 40. (withdrawn) The polypeptide, as claimed in claim 39, having a sequence of at least 70% identity with the sequence shown in SEQ ID NO:1 from amino acid 37 to 1114.
- 41. (withdrawn) The polypeptide, as claimed in claim 39, having a sequence of at least 80% identity with the sequence shown in SEQ ID NO:1 from amino acid 37 to 1114.
- 42. (withdrawn) The polypeptide, as claimed in claim 39, having a sequence of at least 90% identity with the sequence shown in SEQ ID NO:1 from amino acid 37 to 1114.
- 43. (withdrawn) A polypeptide, as claimed in claim 39, having protease activity.
- 44. (withdrawn) A nucleic acid molecule comprising a sequence encoding a polypeptide having an amino acid sequence as set out in SEQ ID NO:1 from

amino acid 37 to 1114, or a sequence having at least 50% identity thereto, or a functional fragment thereof.

- 45. (withdrawn) A nucleic acid molecule comprising a sequence as set out in SEQ ID NO:2 or a sequence having at least 60% identity thereto, or a sequence which hybridises thereto under stringent conditions.
- 46. (withdrawn) The nucleic acid molecule, as claimed in claim 45, comprising a sequence having at least 70% identity with the sequence shown in SEQ ID NO:2.
- 47. (withdrawn) The nucleic acid molecule, as claimed in claim 45, comprising a sequence having at least 80% identity with the sequence shown in SEQ ID NO:2
- 48. (withdrawn) The nucleic acid molecule, as claimed in claim 45, comprising a sequence having at least 90% identity with the sequence shown in SEQ ID NO:2.
- 49. (withdrawn) A composition for use in raising an immune response in an animal comprising a polypeptide having an amino acid sequence as set out in SEQ ID NO:1 from amino acid 37 to 1114, or a sequence having at least 50% identity thereto, or a functional fragment thereof and optionally a carrier and/or adjuvant.
- 50. (withdrawn) A composition for use in raising an immune response in an animal, comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence as set out in SEQ ID NO:1 from amino acid 37 to 1114, or a sequence having at least 50% identity thereto, or a functional fragment thereof and optionally a carrier and/or adjuvant.
- 51. (withdrawn) A polypeptide having an amino acid sequence as set out in SEQ ID NO:3 from amino acid 26 to 616, or a sequence having at least 50% identity thereto, or a functional fragment thereof.

- 52. (withdrawn) The polypeptide, as claimed in claim 51, having a sequence of at least 70% identity with the sequence shown in SEQ ID NO:3 from amino acid 26 to 616.
- 53. (withdrawn) The polypeptide, as claimed in claim 51, having a sequence of at least 80% identity with the sequence shown in SEQ ID NO:3 from amino acid 26 to 616.
- 54. (withdrawn) The polypeptide, as claimed in claim 51, having a sequence of at least 90% identity with the sequence shown in SEQ ID NO:3 from amino acid 26 to 616.
- 55. (withdrawn) The polypeptide, as claimed in claim 51, having lipase activity.
- 56. (withdrawn) A nucleic acid molecule comprising a sequence encoding a polypeptide having an amino acid sequence as set out in SEQ ID NO:3 from amino acid 26 to 616, or a sequence having at least 50% identity thereto, or a functional fragment thereof.
- 57. (withdrawn) nucleic acid molecule comprising a sequence as set out in SEQ ID NO:4 or a sequence having at least 60% identity thereto, or a sequence which hybridises thereto under stringent conditions.
- 58. (withdrawn) The nucleic acid molecule, as claimed in claim 57, comprising a sequence having at least 70% identity with the sequence shown in SEQ ID NO:4.
- 59. (withdrawn) The nucleic acid molecule, as claimed in claim 57, comprising a sequence having at least 80% identity with the sequence shown in SEQ ID NO:4.

Application. No. 10/069,799
Amendment dated July 27, 2004
Resolute Office Action of February 27

Reply to Office Action of February 27, 2004

- 60. (withdrawn) The nucleic acid molecule, as claimed in claim 57, comprising a sequence having at least 90% identity with the sequence shown in SEQ ID NO:4.
- 61. (withdrawn) A composition for use in raising an immune response in an animal, the composition comprising a polypeptide having an amino acid sequence as set out in SEQ ID NO:3 from amino acid 26 to 616, or a sequence having at least 50% identity thereto, or a functional fragment thereof and optionally a carrier and/or adjuvant.
- 62. (withdrawn) A composition for use in raising an immune response in an animal, the composition comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence as set out in SEQ ID NO:3 from amino acid 26 to 616, or a sequence having at least 50% identity thereto, or a functional fragment thereof and optionally a carrier and/or adjuvant.
- 63. (Currently amended) An isolated A polypeptide having an comprising the amino acid sequence as set out in SEQ ID NO:5, or a sequence having at least 60% identity thereto, or a functional fragment thereof of at least 20 amino acids in length which shows immunological cross-reactivity with said polypeptide.

64-65. (canceled)

- 66. (previously presented) The polypeptide, as claimed in claim 63, having haemolysin activity.
- 67. (currently amended) An isolated A nucleic acid molecule comprising a sequence encoding a polypeptide having an the amino acid sequence as set out in SEQ ID NO:5, or a sequence having at least 60% identity thereto, or a functional fragment thereof of at least 20 amino acids in length which shows immunological cross-reactivity with said polypeptide.

- 68. (withdrawn) A nucleic acid molecule comprising a sequence as set out in SEQ ID NO:6 or a sequence having at least 60% identity thereto, or a sequence which hybridises thereto under stringent conditions.
- 69. (withdrawn) The nucleic acid molecule, as claimed in claim 68, comprising a sequence having at least 70% identity with the sequence shown in SEQ ID NO:6.
- 70. (withdrawn) The nucleic acid molecule, as claimed in claim 68, comprising a sequence having at least 80% identity with the sequence shown in SEQ ID NO:6.
- 71. (withdrawn) The nucleic acid molecule, as claimed in claim 68, comprising a sequence having at least 90% identity with the sequence shown in SEQ ID NO:6.
- 72. (currently amended) A composition for use in raising an immune response in an animal, the composition comprising a polypeptide having an the amino acid sequence as set out in SEQ ID NO:5, or a sequence having at least 60% identity thereto, or a functional fragment thereof of at least 20 amino acids in length which shows immunological cross-reactivity with said polypeptide and optionally a carrier and/or adjuvant.
- 73. (withdrawn) A composition for use in raising an immune response in an animal, the composition comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence as set out in SEQ ID NO:5, or a sequence having at least 60% identity thereto, or a functional fragment thereof and optionally a carrier and/or adjuvant.
- 74. (withdrawn) A composition for use in raising an immune response in an animal directed against *Moraxella*, the composition comprising at least one polypeptide selected from the group consisting of polypeptide as given in SEQ ID NO:1 from

amino acid 37 to 1114, SEQ ID NO:3 from amino acid 26 to 616, and SEQ ID NO:5.

- 75. (withdrawn) The composition of claim 74 wherein said peptide having at least 50% identity to the peptide selected from the group consisting of a peptide as given in SEQ ID NO:1 from amino acid 37 to 1114, SEQ ID NO:3 from amino acid 26 to 616, and SEQ ID NO:5.
- 76. (withdrawn) The composition, as claimed in claim 74, the composition comprising a polypeptide having at least 60% identity to the amino acid sequence as given in SEQ ID NO:5 or a functional fragment thereof, and either one of, or preferably both of, a polypeptide having at least 50% identity to the amino acid sequence as given in SEQ ID NO:1 or a functional fragment thereof and a polypeptide having at least 50% identity to the amino acid sequence as given in SEQ ID NO:3 or a functional fragment thereof.
- 77. (withdrawn) The composition, as claimed in claim 74, wherein the *Moraxella* is *M. bovis* or *M. catarrhalis*.
- 78. (withdrawn) The composition, as claimed in claim 75, wherein the *Moraxella* is *M. bovis* or *M. catarrhalis*.
- 79. (withdrawn) The composition, as claimed in claim 76, wherein the *Moraxella* is *M. bovis* or *M. catarrhalis*.
- . 80. (withdrawn) The composition, as claimed in claim 74, wherein the *Moraxella* is *M. bovis*.
- 81. (withdrawn) The composition, as claimed in claim 75, wherein the *Moraxella* is *M. bovis*.

Application. No. 10/069,799 Amendment dated July 27, 2004 Reply to Office Action of February 27, 2004

- 82. (withdrawn) The composition, as claimed in claim 76, wherein the *Moraxella* is *M. bovis*.
- 83. (withdrawn) An antibody raised against a polypeptide selected from the group consisting of a polypeptide as given in SEQ ID NO:1 from amino acid 37 to 1114 or a functional fragment thereof, SEQ ID NO:3 from amino acid 26 to 616 or a functional fragment thereof, and SEQ ID NO:5 or a functional fragment thereof.
- 84. (withdrawn) The antibody of claim 83 wherein said polypeptide has at least 50% identity to the polypeptide as given in SEQ ID NO:1 from amino acid 37 to 1114 or a functional fragment thereof, SEQ ID NO:3 from amino acid 26 to 616 or a functional fragment thereof, and SEQ ID NO:5 or a functional fragment thereof.